Akero Therapeutics price target raised to $109 from $42 at UBS
UBS raised the firm’s price target on Akero Therapeutics (AKRO) to $109 from $42 and keeps a Buy rating on the shares. Akero reported “strong” ...
STAT15h
RFK Jr.’s confirmation hearings, MASH drugs, and a controversial obesity ad
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Akero Therapeutics Stock Doubles on Liver Data
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
STAT1d
MASH drugs reach a meaningful tipping point for patients and investors
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...
Akero Therapeutics Reports Positive Results from SYMMETRY Study in Recent 8-K Filing
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering. UBS Investment Bank is acting as co-manager for the offering.